Journal article
LDP-02 (Millenium).
Abstract
Millennium (formerly LeukoSite) and Genentech are developing LDP-02, a humanized monoclonal antibody to the alpha4beta7 integrin receptor on leukocytes, for potential use in the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis [274580]. LeukoSite intended to develop iv and sc formulations of LDP-02 for acute IBD [315156]. In December 1997, Genentech entered into a collaboration with LeukoSite to …
Authors
Marshall JK
Journal
Current Opinion in Investigational Drugs, Vol. 2, No. 4, pp. 502–504
Publication Date
4 2001
ISSN
1472-4472